Sydney - Novotech, a leading biotech specialist CRO in the Asia-Pacific region, is sponsoring the ChinaTrials13 conference and will have teams from Novotech’s China offices attending to support biotechs planning clinical trials in China and the Asia-Pacific region (11-21, November 2021). 

The conference brings together China biotechs as well as regional and international firms looking to expedite quality trials.

Of particular focus is oncology research. According to GlobalData, China has the highest incidence of cancer in the world, accounting for 24% of newly diagnosed cases and 30% of cancer-related deaths worldwide in 2020.

Meet the Novotech team at Booth: #11&12

Presentations by Novotech

Workshop: Navigating the Future of Cell Therapies Development: Unlocking the Full Potential

10th November, 9am – 12pm

Qr code

Description automatically generated

Topics include:

  • CAR-T Therapy: Key considerations during clinical development
  • Execution and quality management for cell therapy clinical development
  • Statistical considerations in CAR-T therapy clinical trials

Key Novotech experts along with industry leaders will present, then open up for discussions around key issues. 

Some of the topics covered at the conference include:

  • The Next Phase of Chinese Innovative Biotech Drug Development
  • China+US Development: Should You File Your IND in the US Before/After or Simultaneously Alongside Your China IND?
  • China CMO Roundtable: What's On the Minds of China's Top CMO's?
  • Decentralized Clinical Studies: How COVID-19 Changed Clinical Development & Lessons Learned
  • Regulatory Insights: Taking Advantage of Fast Track Channels
  • MNC Perspectives: China's New Role in Global Development
  • Global Drug Development 2.0: Borderless Innovation
  • Cell & Gene Therapy Drug Development in China: What's Next?
  • Experience Sharing: China Biotech + MNC Pharma Drug Development Partnerships 
  • Digital Technology to Support Remote Inspection to Accelerate Clinical Research: PI, Site and Sponsor Perspectives
  • Choosing the Right Clinical Development Strategy to Optimize Regulatory Approval Pathway
  • Win From the Start: Early Clinical Research Strategies for Innovative Drugs
  • Strategy & Planning of Innovative Drugs in MRCT
  • How to Design Trials to Better Serve the Needs of Clinical & Needs of Patients
  • Strategies for Moving Quickly from Phase I to Phase II
  • Seamless Global Development from Phase I to III: A Tale of COVID-19 Antibody Cocktail Therapy 
  • Real World Data: The Road to Bringing Innovative Therapies to Patients Faster?


1. Home to around 20% of the world’s population, research regulatory reform creates tremendous opportunity for Western biotechs in China - Clinical Trials Arena

 

Media contact

About Novotech Novotech-CRO.com 

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase. 

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006. 

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice. 

For more information or to speak to an expert team member visit www.Novotech-CRO.com